FDA Accepts Novartis/Sandoz Regulatory Submission for Proposed Biosimilar to Enbrel

By: via Benzinga
Sandoz, a Novartis (NYSE: NVS) company and the global leader in biosimilars, announced today that the US Food and Drug Administration ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.